U.S. Markets closed

Bovie Medical Corporation (BVX)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
2.44+0.06 (+2.52%)
At close: 4:02PM EDT
People also watch
AOICASMPDEXTSTCRVP
  • Under $2, as I predicted. BVX shares are now lower than when Gershon was named CEO in December 2013, but it’s even a sadder story for shareholders. Gershon has slashed shareholder equity by almost 50 percent, doubling the number of outstanding shares from about 17 million to more than 30 million. To justify this catastrophic dilution, Bovie revenue would have had to double, which, needless to say, never will happen. Outside of paying salaries, bonuses and other compensation, where really did that money go? Meanwhile, the jplasma launch was more than a failure, it was a debacle. The overpaid Geshon and McCarthy continue to destroy the company, and even more shamefully, the past incompetent management team of Makrides, Saron and Citronowicz remain on the payroll and pull down lavish salaries and benefits considering the size and lack of performance of the company. Question for shareholders: When does incompetence rise to the level of criminality? When does giving information that you as a corporate executive should know is patently false become fraud?
  • Gershon’s “guidance” is so implausible it borders on fraudulent. He is predicting “60% to 80% year-over-year” growth in advanced energy (jPlasma), yet jplasma sales have declined sharply from $1.4M in Q3-2016 to $970,000 in Q4-2017 to a shockingly low $607,000 in Q12017. (This number is even less than Q2-2016!) He also admits that OEM revenue will decline 25% to 35% year-over-year, which means -- considering this incompetent nonentity’s track record -- the decline will be even more. His overall revenue “guidance” of a gain of 5-10 percent year-over-year is a fairytale. Maybe he’s assuming that the scratch-off lottery ticket he bought will pay off and that’s part of the “guidance”? Actually, buying lottery tickets has a better chance of paying off than Bovie stock. Can someone tell me how this inept pipsqueak carnival huckster and his Chief Noncommercialization Officer are allowed to keep their jobs? If they’re waiting for the stock to dip below $1, they won’t have to wait too much longer.
  • Anyone who held on after the Hologic deal blew up so fast was crazy, but the signs of the destruction of this once promising company have been going on for years. In the past, Gershon would chirp about jPlasma “metrics” such as hospital approvals, generators sold, generators in use, handpieces sold, etc., etc. All these metrics indicate if a product is selling -- or not selling. Not surprisingly, this inept CEO doesn’t even bother with any metrics or data or numbers anymore, an indication jplasma is a failure. He has very little stake in BVX stock, so why should he care about the stock price. He and his “management team” can’t get bonuses by hitting performance targets, but they got bonuses for successful dilutions -- in effect stealing money from shareholders and putting it in their pockets. The fact that no one has gotten fired indicates the Board knows nothing can save this company, so they’ll just all go down with the ship -- collecting hefty paychecks until it finally sinks.
  • Earnings are an unmitigated disaster. JPlasma sales fell 37% sequentially, and have fallen for 2 straight quarters. Yet, the pipsqueak carnival huckster on March 9, when the 1st quarter was 75% over and he knew how the quarter would look, said “We expect sequential growth quarter-over-quarter and that includes Q1.” Which means, either a) Bovie didn’t sell a single jplasma product from March 10-31; b) people returned jplasma products from March 10-31; c) Gershon is delusional; d) Gershon was lying. Now you know why they did they dilution. They are running out of money. This scam has been going on for more than 10 years now. Tomorrow, the stock crashes. It is all over for Jplasma, it is probably all over for Bovie.
  • As predicted, the stock is cratering. The “guidance” fraud is the same transparent trick Gershon pulled after the Hologic deal blew up, when he ordered a press release “confirming” an outlook that was false. And on March 9, this incompetent nonentity actually said sequential revenue in Q1 would be higher, when he had to know that was false. As for the conference call, Gershon made sure to hog all the time with inanities so there would be less time for questions, which he knew he couldn’t answer. And where was the chief noncommercial officer on the call? He usually likes to chime in with alternative-facts, but I didn’t hear him at all. Maybe he was planning the next dilution, when Bovie is at 10 cents a share.
  • 136,000 shares short. 23,200,000 float? No place to go but up!
  • Been aware for a while, but it’s all the same. Nothing ever changes. The useless Wise still posts his useless links to useless patents, while also posting the same alt-nut conspiracy theories he’s done for the past 10 years. Makrides, Saron and Moshe still draw huge paychecks for doing -- what? Meanwhile, Bovie just sinks and sinks. The only chance they had was Hologic, and that blew up after just a few months. The rumors why it blew up, if true, are unsettling. Maybe carnival barker Gershon and chief noncommercialization officer McCarthy --AKA the Dilution Boys -- will address it at the next CC (Yeah, sure). It looks like Q1 will be another disaster. But at least that will prevent the Dilution Boys from doing what they do best -- diluting their shareholders.
  • Bike...you're as big of a jackass as Trump.
  • Cold plasma sanitizing device
    Complete Patent Searching Database and Patent Data Analytics Services.
    www.freepatentsonline.com
  • The scenarios are quite interesting at current levels for BVX. Yo you should really check out awe-someSTOCKS, they seem on point with their stocks.
  • The top line was $300,000 less than what analysts had estimated. A miss, but not a big one. Horrific? No way. And J Plasma sales in 4Q vs. 3Q is comparing apples to oranges as 3Q benefitted from supplying Hologix with demos. So it is not that the 4Q was bad; it is just that the 3Q was clearly higher than usual due to the Hologix deal. So the comparisons are not valid.
  • Company is cash flow positive in Q3 and Q4. They have no debt. Four holders own 30% of stock and have been adding. No insider sales. Modest options pool. Basically solid product line with wildcat product that could be very big. Potential acquisition target especially with Great Point involved. Buy.
  • BVX = Sandbagger: Meaning "pretend weakness"
  • I minor shortfall in revenue and it drops 17%. The weak hands depart and we move in. Stayed on the bid side all day and picked up a lot of stock. Only 2% of stock traded so just minor odd lot selling. The story stays intact.
  • ...213,800 shares short, down from 403,000.share price increase at earnings? Come on Bovie.
  • The last time BVX did something like this it blew up. Things look enticing now that performance %(week) has hit 4.17%. google awesom-eSTOCKS - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • This" the two companies could not come to a mutually acceptable financial arrangement." is code for not enough absolute gross margin available for two companies to share and make a business case. The large potential market fro JP is created by Bovie itself by high pricing for a "disposable". If the customer is not willing to pay that ... and the handpiece is also reusable, Bovie need to spell out the implications. IF the generator is sold at cost, and surgeons only use it as a last resort then this is not going to work out financially.
  • The just released J-plasma update certainly has encouraging news ..... the Hologic part isn't great when viewing from a distance, but I'm guessing Gershon and Saron have other ideas to make up for that lost item.
  • WOW! The Biotech Showcase 2017 in San Fran sure did great things for the stock price! Sighhhhhhhhhhhhhhhhhh.
  • SEC Form 8-K filed December 19, 2016

    Item 5.02 Departure of Directors or Principal Officers; Election of Directors;Appointment of Principal Officers

    Bovie Medical Corporation (the “Company”) recently received notification from Great Point Partners, LLC (“GPP”) that GPP irrevocably waives, among other things, their previously disclosed right to nominate two (2) directors to the Company’s Board of Directors (the “Board”). On December 19, 2016, the Company received notification from Scott Davidson and Charles T. Orsatti, GPP’s nominees to the Board, that they each resign from the Board, effective as of December 19, 2016, and December 31, 2016, respectively. Messrs.Orsatti’s and Davidson’s departures from the Board were not the result of any disagreements with the Company. The Company is actively seeking one (1) or more independent directors to fill the resulting vacancies on the Board.